Decreased histone deacetylase activity in chronic obstructive pulmonary disease.

By Kazuhiro Ito, Misako Ito, W. Elliott, B. Cosío, G. Caramori, O. Kon, A. Barczyk, S. Hayashi, I. Adcock, J. Hogg and 1 more. New England Journal of Medicine, 2005

1,026 citations recorded by the source corpus.

Subfields: Molecular Biology, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/79b8fa2324aa42502542fb5a6bbcdce2d4f01fac

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Molecular Biology

1. Xiang-Jiao Yang
2. E. Seto
3. Minoru Yoshida
4. P. Barnes
5. J. Rock
6. H. Chapman
7. E. Morrisey
8. B. Hogan

In Pulmonary and Respiratory Medicine

1. J. Rock
2. E. Morrisey
3. P. Barnes
4. B. Stripp
5. B. Hogan
6. C. E. Barkauskas
7. S. Randell

Citations in the corpus

• HATs and HDACs: from structure, function and regulation to novel strategies for therapy and prevention (2007, background): “Adverse conditions such as smoking were reported to alter the expression of class I/II HDACs in smokers (Ito et al., 2005).”
• Repair and regeneration of the respiratory system: complexity, plasticity, and mechanisms of lung stem cell function (2014, background): “tient biopsies show a correlation between disease progression and loss of HDAC2 expression and activity, but lower HDAC activity is resistant to anti-inflammatory steroid therapy (Ito et al., 2005).”
• Regulation of inflammation and redox signaling by dietary polyphenols. (2006, background): “[89] Ito K, Ito M, Elliott W, Borja Cosio B, et al.”
• Erasers of histone acetylation: the histone deacetylase enzymes. (2014, background): “Perhaps this is best illustrated by the observation that HDAC2 expression and activity are reduced in lung macrophages, biopsies, and blood cells from patients with chronic obstructive pulmonary disease (COPD) and asthma (Ito et al. 2005).”
• Immunology of asthma and chronic obstructive pulmonary disease (2008, background): “This appears to be related to decreased activity and expression of HDAC2 in the inflammatory cells and peripheral lungs of COPD patient”
• How corticosteroids control inflammation: Quintiles Prize Lecture 2005 (2006, background): “Although this is seen in all stages of COPD it is most marked in the patients with the most severe disease when HDAC2 expression is reduced by more than 95% compared to nonsmokers (Ito et al., 2005).”